Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s stock price traded up 7.7% on Thursday . The stock traded as high as $1.95 and last traded at $1.95. 191,308 shares were traded during mid-day trading, a decline of 91% from the average session volume of 2,183,922 shares. The stock had previously closed at $1.81.
Wall Street Analyst Weigh In
PGEN has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $6.00 price objective (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reiterated a "market outperform" rating and set a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Precigen presently has an average rating of "Hold" and a consensus target price of $7.00.
View Our Latest Research Report on Precigen
Precigen Price Performance
The company has a market capitalization of $489.09 million, a PE ratio of -3.04 and a beta of 1.66. The company has a 50 day moving average of $1.40 and a two-hundred day moving average of $1.09.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Mill Creek Capital Advisors LLC purchased a new stake in Precigen in the third quarter worth about $104,000. Charles Schwab Investment Management Inc. boosted its position in shares of Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company's stock worth $1,158,000 after purchasing an additional 127,467 shares in the last quarter. FMR LLC grew its stake in shares of Precigen by 26.4% in the 3rd quarter. FMR LLC now owns 345,204 shares of the biotechnology company's stock worth $327,000 after buying an additional 72,033 shares during the last quarter. HighTower Advisors LLC increased its position in Precigen by 186.8% during the 3rd quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company's stock valued at $179,000 after buying an additional 125,145 shares in the last quarter. Finally, Stifel Financial Corp raised its stake in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after buying an additional 15,680 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
